

Supplementary Table 2. Differences between low and high DOAC exposure (n=211)

Variable	Low DOAC exposure (AUC <0.5) (n=133, 63.0%)	High DOAC exposure (AUC ≥0.5) (n=78, 37.0%)	Descriptive P
Female sex	67 (50.4)	40 (51.3)	0.899 [‡]
Age (yr)	80 (74–86)	80 (76–86)	0.452 [§]
Body weight (kg)	75 (65–85) 124 (93.2)	75 (65–84) 77 (98.7)	0.977 [§]
Ischemic stroke	107 (80.5)	50 (64.1)	0.014 [‡]
TIA	26 (19.5)	28 (35.9)	
Large vessel occlusion (ICA, MCA [1–3], PCA, ACA, BA)	51 (38.3)	20 (25.6)	0.059 [‡]
Time of ischemic stroke/TIA (00:00–7:59)*	24 (18.0)	21 (26.9)	0.129 [‡]
Time of ischemic stroke/TIA (8:00–15:59)*	71 (53.4)	35 (44.9)	0.233 [‡]
Time of ischemic stroke/TIA (16:00–23:59)*	38 (28.6)	22 (28.2)	0.955 [‡]
Functional impairment			
Admission NIHSS of patients with ischemic stroke	7 (3–18)	5 (2–11)	0.020 [§]
Premorbid modified Rankin Scale	2 (0–3)	1 (0–3)	0.353 [§]
Modified Rankin Scale at 3 months	3 (1–5) 124 (93.2)	2 (0–4) 75 (96.2)	0.016 [§]
Comorbidities			
Arterial hypertension	120 (90.2)	70 (89.7)	0.910 [‡]
Diabetes	45 (33.8)	23 (29.5)	0.514 [‡]
Hypercholesterolemia	74 (55.6)	45 (57.7)	0.772 [‡]
Previous stroke or TIA	45 (33.8)	29 (37.2)	0.623 [‡]
Congestive heart failure	26 (19.5)	14 (17.9)	0.775 [‡]
Vascular disease	70 (52.6)	44 (56.4)	0.595 [‡]
Atrial fibrillation	120 (90.2)	72 (92.3)	0.610 [‡]
Premorbid CHA ₂ DS ₂ -VASc score	5 (4–6)	5 (4–6)	0.401 [§]
Creatinine at admission (mg/dL)	0.89 (0.75–1.13)	0.98 (0.78–1.16)	0.658 [§]
eGFR (mL/min) [†]	65.08 (50.3–85.0) 107 (80.5)	56.27 (43.0–77.0) 60 (76.9)	0.081 [§]
Pharmacotherapy			
Apixaban	62 (46.6)	17 (21.8)	<0.001 [‡]
Edoxaban	16 (12.0)	4 (5.1)	0.099 [‡]
Rivaroxaban	38 (28.6)	50 (64.1)	<0.001 [‡]
Dabigatran	17 (12.8)	7 (9.0)	0.400 [‡]
Additional antiplatelet therapy	12 (9.0)	7 (9.0)	0.832 [‡]
Time between last DOAC intake and admission (min)	635 (294–942)	523 (280–788)	0.264 [§]
Time between DOAC intake and event (min)*	505 (18–725) 118 (88.7)	450 (235–645) 61 (78.2)	0.138 [§]
Prescription quality			
DOAC adherence to SmPCs: underdosed	38 (28.6)	13 (16.7)	0.051 [‡]
DOAC adherence to SmPCs: correctly dosed	93 (69.9)	60 (76.9)	0.272 [‡]
DOAC adherence to SmPCs: overdosed	2 (1.5)	5 (6.4)	0.055 [‡]

Values are presented as number (%) or median (interquartile range).

DOAC, direct oral anticoagulant; AUC, area under the curve; TIA, transient ischemic attack; ICA, internal carotid artery; MCA (1–3), middle cerebral artery (segments 1–3); PCA, posterior cerebral artery; ACA, anterior cerebral artery; BA, basilar artery; NIHSS, National Institutes of Health Stroke Scale; eGFR, estimated glomerular filtration rate; SmPC, recommended doses from summaries of product characteristic.

*Concentration subgroup only (total n=179/211; 84.8%); [†]eGFR according to Cockcroft-Gault formula; [‡]Chi-square; [§]t-test.